Last week, Pear Therapeutics and Sandoz announced the commercial launch of reSET®.
This is the only FDA-authorized prescription digital therapeutic for patients with Substance Use Disorder (SUD) and is available immediately for clinicians to prescribe to their patients.
Results from multicenter, randomized clinical trials demonstrated that reSET® significantly improved abstinence in substances of abuse and increased retention when used with outpatient therapy and contingency management, in comparison to outpatient therapy alone.
This commercial launch is another exciting milestone for digital therapeutics – and further adds to the mounting body of evidence that supports the advancement of clinically validated digital interventions.
You can access the full press release here via Business Wire: